Our top resource picks

Article
Dapagliflozin: UK court reaffirms plausibility standard despite G 2/21
In a significant UK ruling in Generics, Teva & Glenmark v AstraZeneca [2025] EWHC 1012 (Pat), the High Court of England and Wales provided a comprehensive restatement of how inventive step and sufficiency are assessed in the UK in light...
Learn more-
Article
Dapagliflozin: UK court reaffirms plausibility standard despite G 2/21
In a significant UK ruling in Generics, Teva & Glenmark v AstraZeneca...
-
Article
Key considerations when patenting bispecific antibodies in Europe
Technology overview Bispecific monoclonal antibodies (BsAbs) are antibody constructs that create additional...
-
Article
Webinar: European design reforms from 1 May 2025
Reform of designs in the EU is now in full swing, with...
-
Article
Key considerations when patenting chimeric antigen receptor technologies in Europe
We explore the therapeutic indications addressed by Chimeric Antigen Receptors (CARs) and...
All resources
Filters